Amylyx Pharmaceuticals Inc (AMLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) has a cash flow conversion efficiency ratio of -0.091x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.90 Million) by net assets ($305.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Amylyx Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AMLX current and long-term liabilities for a breakdown of total debt and financial obligations.
Amylyx Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amylyx Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xinjiang Joinworld Co Ltd
SHG:600888
|
0.014x |
|
Veris Residential Inc
NYSE:VRE
|
0.011x |
|
Vcanbio Cell & Gene Engineering Corp Ltd
SHG:600645
|
0.028x |
|
A10 Network
NYSE:ATEN
|
0.107x |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
0.068x |
|
JetBlue Airways Corp
NASDAQ:JBLU
|
-0.063x |
|
Avi Ltd
JSE:AVI
|
0.245x |
|
Hyundai Doosan Infracore Co Ltd
KO:042670
|
0.072x |
Annual Cash Flow Conversion Efficiency for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Amylyx Pharmaceuticals Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see Amylyx Pharmaceuticals Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $305.26 Million | $-123.34 Million | -0.404x | +60.29% |
| 2024-12-31 | $164.76 Million | $-167.65 Million | -1.017x | -3800.09% |
| 2023-12-31 | $433.43 Million | $11.92 Million | 0.027x | +105.21% |
| 2022-12-31 | $340.61 Million | $-179.87 Million | -0.528x | -206.73% |
| 2021-12-31 | $-151.17 Million | $-74.80 Million | 0.495x | -10.03% |
| 2020-12-31 | $-66.72 Million | $-36.70 Million | 0.550x | +30.49% |
| 2019-12-31 | $-25.36 Million | $-10.69 Million | 0.421x | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more